Pulished Date August, 2019
ID: 273
Share on
Share on

Asia-Pacific Hemophilia Management Market By Type (Hemophilia A, Hemophilia B) By Drug (Octocogalfa, Nonacogalfa, Desmopressin And Other Drugs) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts(2018-2023)

Pulished: August, 2019
ID: 273
Pages: 139

Overview of the Market:
Asia-Pacific Hemophilia Management Market
was worth $1020 million in 2018 and estimated to be growing at a CAGR of 1.78%, to reach $1110 million by 2023. Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males born each year contains some form of hemophilia. Hemophilia is characterized into three levels depending upon on its severity as severe, moderate and mild. Around 80% of the patients suffering from hemophilia are considered to be severe. The worldwide incidence of hemophilia is estimated at more than 400,000 people. Asia-Pacific Hemophilia Management market is driven by factors such as growing prevalence of the disease and increasing usage of recombinant product. Advancements in technology and rising investments into Research and developments are also fuelling the market growth. However lack of awareness about the disease and limited access to the medication are the key factors hindering the market growth. Advancements in gene therapy which help in the treatment of hemophilia also provide immense growth opportunities. Asia-Pacific Hemophilia management market is segmented on the basis of type of hemophilia and type of drug. By type of hemophilia it is further sub segmented into Hemophilia A and Hemophilia B. On the basis of drug type it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A is the largest segment accounting for approximately XX% due to elevated incidence of the condition.

Geographical Analysis: 
Based on geography Asia-Pacific hemophilia management market is analyzed under various regions namely China, India, Japan, South Korea and Australia. Asia-Pacific region is estimated to be the fastest growing region owing to its high population base and increasing healthcare expenditure. Within Asia-Pacific, Japan is a major market for hemophilia management due to high government support and wide spread awareness about the treatment options for hemophilia. India is estimated to grow at highest CAGR due to increasing incidence of the hemophilia.

Key Players in this Market: 
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 BY Type                                        

                                5.1.1 Hemophilia A                         

                                5.1.2 Hemophilia B                          

                5.2 By Drug                                        

                                5.2.1 Octocogalfa                            

                                5.2.2 Nonacogalfa                           

                                5.2.3 Desmopressin                       

                                5.2.4 Other drugs                            

  1. Geographical Analysis

                6.3 Asia-Pacific                                 

                                6.1 Introduction                               

                                6.2 China                             

                                6.3 India                              

                                6.4 Japan                            

                                6.5 South Korea                               

                                6.6 Australia                      

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Biogen                                          

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Baxter International Inc.                                       

                8.4 Bayer Pharma AG                                    

                8.5 Novo Nordisk A/S                                    

                8.6 Grifols International SA                                         

                8.7 CSL Behring                                

                8.8 Octapharma                                               

                8.9 Swedish Orphan Biovitrum AB                                           

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 


a) List of Tables

b) List of Figures

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Hemophilia Management Market By Region, From 2018-2023 (USD Million)
  2. Asia-Pacific Hemophilia Management Market By Type, From 2018-2023 (USD Million)
  3. Asia-Pacific Hemophilia-A Market By Region, From 2018-2023 (USD Million)
  4. Asia-Pacific Hemophilia-B Market By Region, From 2018-2023 (USD Million)
  5. Asia-Pacific Hemophilia Management Market By Drug, From 2018-2023 (USD Million)
  6. Asia-Pacific Octocogalfa Market By Region, From 2018-2023 (USD Million)
  7. Asia-Pacific Nonacogalfa Market By Region, From 2018-2023 (USD Million)
  8. Asia-Pacific Desmopressin Market By Region, From 2018-2023 (USD Million)
  9. Asia-Pacific Other drugs Market By Region, From 2018-2023 (USD Million)
  10. China Hemophilia Management Market By Type, From 2018-2023 (USD Million)
  11. China Hemophilia Management Market By Drug, From 2018-2023 (USD Million)
  12. India Hemophilia Management Market By Type, From 2018-2023 (USD Million)
  13. India Hemophilia Management Market By Drug, From 2018-2023 (USD Million)
  14. Japan Hemophilia Management Market By Type, From 2018-2023 (USD Million)
  15. Japan Hemophilia Management Market By Drug, From 2018-2023 (USD Million)
  16. South Korea Hemophilia Management Market By Type, From 2018-2023 (USD Million)
  17. South Korea Hemophilia Management Market By Drug, From 2018-2023 (USD Million)
  18. Australia Hemophilia Management Market By Type, From 2018-2023 (USD Million)
  19. Australia Hemophilia Management Market By Drug, From 2018-2023 (USD Million)

Please wait. . . . Your request is being processed


$ 1234 3335

Click for Request Sample